申请人:Eli Lilly and Company
公开号:US20170354641A1
公开(公告)日:2017-12-14
The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
本发明涉及某些新颖的2,3-二氢-1H-吲哚化合物,包括这些化合物的药物组合物,以及使用这些化合物治疗癌症的方法,更具体地用于治疗来自包括黑色素瘤、急性髓样白血病、慢性淋巴细胞白血病、结直肠癌、乳腺癌、肺癌、卵巢癌、输卵管癌、原发性腹膜癌、子宫颈癌、胃癌、肝癌、胰腺癌、甲状腺癌、胶质瘤、非霍奇金淋巴瘤和霍奇金淋巴瘤等癌症的治疗。